Supernus Pharmaceuticals (SUPN) EBIT Growth (1y) (2012 - 2026)
Supernus Pharmaceuticals (SUPN) EBIT Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -150.77% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -10.00% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -0.93% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -9.25% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -97.30% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 4.05% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 12.73% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn | -577.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -577.42% |
| Dec 31, 2025 | -118.39% |
| Sep 30, 2025 | -247.46% |
| Jun 30, 2025 | -46.20% |
| Mar 31, 2025 | -225.28% |
| Dec 31, 2024 | 2,249.10% |
| Sep 30, 2024 | 401.90% |
| Jun 30, 2024 | 228.33% |
| Mar 31, 2024 | -160.92% |
| Dec 31, 2023 | -102.90% |
| Sep 30, 2023 | 634.34% |
| Jun 30, 2023 | -255.01% |
| Mar 31, 2023 | 163.14% |
| Dec 31, 2022 | 463.04% |
| Sep 30, 2022 | -104.67% |
| Jun 30, 2022 | -66.74% |
| Mar 31, 2022 | -85.11% |
| Dec 31, 2021 | -85.82% |
| Sep 30, 2021 | -41.92% |
| Mar 31, 2021 | -54.45% |